Skip to content
Clinical Trials – home

Azienda Ospedaliera di Padova

Verified siteinfo

Italy Via Nicolo' Giustiniani 2, 35128 Padua, Italy

  • 180 trials recruiting
  • Colitis ulcerative · Chronic lymphocytic leukaemia · Hereditary angioedema
  • Adults and children

About Specializations

Azienda Ospedaliera di Padova in Padua, Italy specialises in clinical trials of conditions such as Colitis ulcerative, Chronic lymphocytic leukaemia, Hereditary angioedema, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Hepatology

The medical center is at the forefront of research in gastroenterology and hepatology, focusing on innovative treatments for conditions such as ulcerative colitis and alcohol-related liver disease.

  • Ulcerative Colitis
  • Alcohol-Related Liver Disease
  • Primary Biliary Cholangitis

Through rigorous clinical trials, the center is advancing therapeutic options that aim to improve patient outcomes and quality of life.

Dermatology and Wound Care

Specializing in dermatology and wound care, the center is pioneering research into novel skin graft products for treating full-thickness skin defects.

  • Skin Graft Innovations
  • Scar Quality Assessment

These advancements are crucial for enhancing healing processes and minimizing scarring in patients with significant skin injuries.

Nephrology

The center is a leader in nephrology research, focusing on conditions like C3 glomerulopathy and lupus nephritis.

  • C3 Glomerulopathy
  • Lupus Nephritis
  • IgA Nephropathy

By exploring new treatment modalities, the center aims to improve renal function and patient survival rates.

Oncology

In the field of oncology, the center is conducting groundbreaking research on langerhans cell histiocytosis and choroidal melanoma.

  • Langerhans Cell Histiocytosis
  • Choroidal Melanoma

These studies are pivotal in developing targeted therapies that aim to reduce mortality and improve long-term outcomes.

Cardiology

The center excels in cardiology research, particularly in managing coronary artery disease and calcific aortic valve stenosis.

  • Coronary Artery Disease
  • Calcific Aortic Valve Stenosis

Innovative diagnostic and therapeutic approaches are being developed to enhance cardiovascular health and patient care.

Neurology

Focusing on neurology, the center is advancing research in Parkinson's disease and amyotrophic lateral sclerosis.

  • Parkinson's Disease
  • Amyotrophic Lateral Sclerosis

These efforts are directed towards developing therapies that slow disease progression and improve neurological function.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Site location
Via Nicolo' Giustiniani 235128 PaduaItaly
Recruiting now
180 trials
Conditions studied
252
Partner status
Verified site

More sites in PaduaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

427 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MH002
  • Sponsor:Microbial Resource Management Health

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Celldex Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A study of navenibart for long-term safety in patients with hereditary angioedema

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Navenibart
  • Sponsor:Astria Therapeutics Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.